Evidence map›Paper›PMID 41407455›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[How I treat acquired clotting factor deficiency].

L Zhang, W J Gu

Abstract readEnglish AbstractCase Reports
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

L ZhangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
W J GuState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired clotting factor deficiency encompasses bleeding disorders with diverse causes, including clotting factor inhibitors, liver disease, and disseminated intravascular coagulation. Among these, acquired clotting factor inhibitors are particularly rare and diagnostically challenging. Clinical management focuses on early recognition of bleeding, individualized therapy, and dynamic monitoring. In China, standardized protocols exist for acquired hemophilia A, while reports on other rare inhibitors are limited. Treatment strategies target both hemostasis and inhibitor eradication, with novel therapies for refractory cases. This article integrates clinical cases to provide practical guidance for standardized management.

Indexed as

Coagulation Protein DisordersAdultHemophilia AHumansMaleMiddle Aged

Identifiers

PMID41407455
PMCPMC12708948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.